【PAILONG BIOMEDICAL INC.】Announcement of Change in Capital Increase Fund Utilization Plan for 2025
NQ Score
0/100
N1 Content Completeness
85
AI Summary (NQ-processed)
PAILONG BIOMEDICAL INC. announced a change in the utilization plan for funds raised from its 2025 cash capital increase. Driven by accelerated approval for PL001 and preferential policies in the Chinese market, some funds will be reallocated to working capital and investment in its Chinese subsidiary.